We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+8.63%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$9.44B
AUM Growth
-$323M
Cap. Flow
-$311M
Cap. Flow %
-3.3%
Top 10 Hldgs %
61.29%
Holding
95
New
24
Increased
17
Reduced
2
Closed
10

Top Buys

Rank Stock Value
1
SGP
SpyGlass Pharma
SGP
+$216M
2
WVE icon
Wave Life Sciences
WVE
+$114M
3
ZLAB icon
Zai Lab
ZLAB
+$106M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$75.5M
5
NUVL
Nuvalent
NUVL
+$66.7M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$743M
2
RNAM
Avidity Biosciences
RNAM
+$623M
3
ACLX
Arcellx
ACLX
+$82.6M
4
BLTE
Belite Bio
BLTE
+$69.2M
5
IVVD icon
Invivyd
IVVD
+$42.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Financials 0.22%
3 Miscellaneous 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
26
Spyre Therapeutics
SYRE
$8.25B
$81.8M 0.87%
1,621,620
– –
EVMN
27
Evommune Inc
EVMN
$489M
$80.3M 0.85%
3,494,638
+35,868
+1% +$811K
CLYM
28
Climb Bio
CLYM
$865M
$77.4M 0.82%
11,300,939
+7,111
+0.1% +$41K
SLDB icon
29
Solid Biosciences
SLDB
$1.09B
$67.2M 0.71%
9,339,978
+3,528,555
+61% +$22.7M
ARTV
30
Artiva Biotherapeutics
ARTV
$584M
$63.5M 0.67%
9,853,302
– –
DMRA
31
Damora Therapeutics
DMRA
$1.89B
$62.1M 0.66%
+2,399,310
New +$61.7M
XNCR icon
32
Xencor
XNCR
$2.15B
$59.1M 0.63%
+4,897,237
New +$60.8M
LBRX
33
LB Pharmaceuticals
LBRX
$1.54B
$54.5M 0.58%
2,208,604
– –
JBIO
34
Jade Biosciences
JBIO
$1.35B
$51.6M 0.55%
3,671,083
– –
ABOS icon
35
Acumen Pharmaceuticals
ABOS
$219M
$49.5M 0.52%
20,992,669
+6,060,606
+41% +$15.5M
FDMT icon
36
4D Molecular Therapeutics
FDMT
$824M
$47M 0.5%
5,049,779
-603,432
-11% -$5.25M
FULC icon
37
Fulcrum Therapeutics
FULC
$294M
$46.4M 0.49%
6,053,960
– –
CAPR icon
38
Capricor Therapeutics
CAPR
$585M
$45.8M 0.49%
1,507,844
– –
IPSC icon
39
Century Therapeutics
IPSC
$404M
$40.1M 0.43%
+17,754,430
New +$37.3M
OLMA icon
40
Olema Pharmaceuticals
OLMA
$944M
$38.8M 0.41%
2,600,000
– –
LENZ
41
LENZ Therapeutics
LENZ
$151M
$38.2M 0.41%
4,178,823
– –
MNPR icon
42
Monopar Therapeutics
MNPR
$765M
$36.6M 0.39%
667,207
– –
PEPG icon
43
PepGen
PEPG
$213M
$35.5M 0.38%
20,064,545
– –
DSGN icon
44
Design Therapeutics
DSGN
$954M
$31.6M 0.34%
2,972,973
+1,511,592
+103% +$15.3M
MIRM icon
45
Mirum Pharmaceuticals
MIRM
$6.08B
$29.4M 0.31%
+318,554
New +$30M
BIOA
46
BioAge Labs
BIOA
$463M
$28.9M 0.31%
+1,650,648
New +$31.8M
LXEO icon
47
Lexeo Therapeutics
LXEO
$409M
$28.7M 0.3%
5,000,000
– –
ASMB icon
48
Assembly Biosciences
ASMB
$709M
$28.3M 0.3%
1,020,410
– –
RZLT icon
49
Rezolute
RZLT
$480M
$28M 0.3%
9,180,000
– –
AKTS
50
Aktis Oncology
AKTS
$1.46B
$26.9M 0.28%
+1,503,084
New +$29.2M
1
2
3 4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, RA Capital Management held 95 positions worth $9.44B, down 3.3% from $9.76B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

RA Capital Management withdrew a net $311M in Q1 2026, closing 10 positions and reducing 2 holdings. Its most notable exit was Cidara Therapeutics, an estimated $743M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, RA Capital Management opened a new position in SpyGlass Pharma worth $208M.

  • RA Capital Management's largest Q1 2026 buy was SpyGlass Pharma: 8,021,117 shares worth $208M.
  • RA Capital Management added most to Wave Life Sciences in Q1 2026, an estimated $114M increase.
  • RA Capital Management's biggest Q1 2026 reduction was Contineum Therapeutics, cutting an estimated $11.9M.
  • RA Capital Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $743M.
  • RA Capital Management's ten largest holdings make up 61% of its $9.44B portfolio in Q1 2026.
  • RA Capital Management opened 24 new positions and closed 10 in Q1 2026.
  • RA Capital Management's portfolio value fell 3.3% quarter-over-quarter to $9.44B.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.